Specific Protocols Open for Enrollment
1. Clinical Trials of FTI Radiosensitization/ A Phase I Trail of the Farnesyltranferase Inhibitor R115777 and Radiotherapy in patient with Non-Small Cell Lung Cancer
UPCC #3501
NCI/CTEP #5150
IRB #703723
PI: Stephen Hahn
Approved by IRB: Open to enrollment: 10 enrolled
Coordinator Sue Prendergast
2. A Phase I Trial of the HIV Protease Inhibitor Nelfinavir and Concurrent Radiation and Chemotherapy in Patients with Stage III Non-Small Cell Lung Cancer.
UPCC #20203
NCI/CTEP #6407
IRB #708871
PI: Stephen Hahn/ Anjali Gupta
Pending IRB approval
Coordinator Sue Prendergast
3. Assessment of Hypoxia in Malignant Gliomas Using EF5
NCI Protocol #4950
IRB Protocol #702859
UPCC #1301
PI: Kevin Judy
Approved by IRB: Open to enrollment: 20 enrolled
Coordinator Sue Prendergast
4. Does Hypoxia Predict Radiation/Surgical Tumor Response/A Correlative Trial of EF5, An Agent for the Detection of Tumor Hypoxia
IRB Protocol #701019
UPCC #3300
NCI #3950
PI: Stephen Hahn
Approved by IRB: Open to accrual: 30 enrolled
Coordinator Sue Prendergast
5. Prospective Analysis of the Phosphatidylinositol 3-kinase-AKT Pathway in Lung Cancer
IRB Protocol # 801743
UPCC #04504
PI: Stephen Hahn
Approved by IRB: Open to accrual: 7 enrolled
Coordinator Sue Prendergast
6. Radiation Therapy Patient Dosimetry
IRB #802379
PI: Stephen Hahn
Approved by IRB: Open to enrollment: 0 enrolled
Coordinator Sue Prendergast
7. An Open-label, Dose Confirmation and Dosimetry Study of Interstitial 131I- chTNT-1/B MAb (COTARATM) for the Treatment of Glioblastoma Multiforme (GBM) at 1st Relapse
PI: Robert Lustig
8. Protocol #802623: Phase II Study of ZD1839 in Patients with Squamous Cell Carcinoma of the Skin
NCI Protocol #6012
UPCC #10304
PI: Robert Lustig
ENT Coordinator Wendy Snyder
9. Phase I Study of BBIC in Normal Human Volunteers
PI: Robert Lustig
10. UPCC 07904: Tempol Skin Study
PI: James Metz
Coordinator Debbie Smith
11. UPCC 10303: Head and Neck PDT study, ALA for Pre-Malignant Lesions
PI: Harry Quon
ENT Coordinator Wendy Snyder
12. UPCC 6899: This is a Phase 1 study for patients with locally recurrent prostate cancer who have previously received definitive XRT.
Pts. receive interstitial PDT to the prostate.
PI: Stephen Hahn
13. UPCC 10203: This is a tissue collection study.
We collect tumor from patients undergoing a Whipple for pancreatic cancer. The two main objectives of this study are: 1.) to prospectively evaluate activation and/or expression of components of the radiation resistance signal transduction pathway in human pancreatic cancer specimens from patients who undergo resection; and 2.) to relate the status of molecular markers in human pancreatic cancers to overall survival, disease-free survival, locoregional failure rate and distant failure rate.
PI: Stephen Hahn
14. UPCC 05503: Patients who have undergone standard platin-based doublet chemotherapy for NSCLC undergo thoracotomy and PDT.
PI: Stephen Hahn
15. UPCC 04305: a clinical trail to evaluate perfusion and metabolism within brain tumors in patients who are going to the operating room from resection of malignant gliomas.
The two main objectives are: to characterize the distributions of blood flow and tumor
choline content obtained by Magnetic Resonance Spectroscopy (MRS) and Continuous
Arterial Spin Labeling (CASL) in malignant gliomas., and to test the association of blood
flow and tumor choline content with hypoxia as measured by cold EF5, hypoxia as
measured by [F-18]-EF5 PET imaging and clinical status (RPA classification)
PI: Stephen Hahn
16. PCC 10304: The purpose of this trial is to (1) assess the safety of administering [18F]-EF5 to patients with brain tumors, (2) investigate the pharmacokinetics and biodistribution of radioactively labeled [18F]-EF5 and (3) to evaluate the ability of PET scanning with [18F]-EF5 to detect hypoxia within brain tumors.
PI: Stephen Hahn
17. UPCC 05901;
This is a companion study for patients enrolled on 05503 who agree to
receive pre op EF5 as well.
PI: Stephen Hahn
» TOP
© University of Pennsylvania | School of Medicine | University of Pennsylvania Health System